• 1
    Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG 1995 The role of prostaglandins in the regulation of bone metabolism. Clin Orthop 313:3646.
  • 2
    Hershman HR 1994 Regulation of prostaglandin synthase-1 and prostaglandin synthase 2. Cancer Metastasis Rev 13:241.
  • 3
    Simmons DL, Levy DB, Yannoni Y, Erikson RL 1989 Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci USA 86:11781182.
  • 4
    Kujubu D, Herschman H 1992 Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 267:79917994.
  • 5
    O'Banion MK, Sadowski HB, Winn V, Young DA 1991 A serum and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 266:23261.
  • 6
    O'Banion MK, Winn V, Young DA 1992 cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 89:4888.
  • 7
    Herschman HR 1996 Prostaglandin synthase 2. Biochim Biophys Acta 1229:125140.
  • 8
    Reddy ST, Herschman HR 1997 Prostaglandin synthase-1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D2 in activated mast cells. J Biol Chem 272:32313237.
  • 9
    Reddy ST, Herschman HR 1994 Ligand-induced prostaglandin synthesis requires expression of the TIS10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages. J Biol Chem 269:1547315480.
  • 10
    Langenbach R, Loftin CD, Lee C, Tiano H 1999 Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann NY Acad Sci 889:5261.
  • 11
    Min YK, Rao Y, Okada Y, Raisz LG, Pilbeam CC 1998 Regulation of prostaglandin G/H synthase-2 expression by interleukin-1 in human osteoblast-like cells. J Bone Miner Res 13:10661075.
  • 12
    Tokushima T, Sato T, Morita I, Murota S 1997 Involvement of prostaglandin endoperoxide H synthase-2 in osteoclast formation induced by parathyroid hormone. Adv Exp Med Biol 433:307309.
  • 13
    Tai H, Miyaura C, Pilbeam CC, Tamura T, Ohsugi Y, Koishihara Y, Kubodera N, Kawaguchi H, Raisz LG, Suda T 1997 Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology 138:23722379.
  • 14
    Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh KS, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T 1999 IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:13451352.
  • 15
    Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T 1998 Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. J Cell Physiol 175:247254.
  • 16
    Jacobs JJ, Sumner DR, Galante JO 1993 Mechanisms of bone loss associated with total hip replacement. Orthop Clin North Am 24:583590.
  • 17
    Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL 1999 Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 154:203210.
  • 18
    Blaine TA, Pollice PF, Rosier RN, Reynolds PR, Puzas JE, O'Keefe RJ 1997 Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents. The role of cAMP-mediated signaling mechanisms. J Bone Joint Surg Am 79:15191528.
  • 19
    al Saffar N, Revell PA 1994 Interleukin-1 production by activated macrophages surrounding loosened orthopaedic implants: A potential role in osteolysis. Br J Rheumatol 33:309316.
  • 20
    Goodman SB, Chin RC, Chiou SS, Schurman DJ, Woolson ST, Masada MPA 1989 Clinical-pathologic-biochemical study of the membrane surrounding loosened and nonloosened total hip arthroplasties. Clin Orthop 244:182187.
  • 21
    Hukkanen M, Corbett SA, Batten J, Konttinen YT, McCarthy ID, Maclouf J, Santavirta S, Hughes SP, Polak JM 1997 Aseptic loosening of total hip replacement. Macrophage expression of inducible nitric oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a possible mechanism for early prosthesis failure. J Bone Joint Surg Br 79:467474.
  • 22
    Boyce BF, Aufdemorte TB, Garrett IR, Yates AJ, Mundy GR 1989 Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 125:11421150.
  • 23
    Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD 1995 Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483492.
  • 24
    Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA 1995 Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:473482.
  • 25
    Zhang X, Morham SG, Langenbach R, Young DA 1999 Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190:451459.
  • 26
    Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 2:11321136.
  • 27
    Mundy GR, Roodman GD, Bonewald LF, Oreffo RO, Boyce BF 1991 Assays for bone resorption and bone formation. Methods Enzymol 198:502510.
  • 28
    Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T 1988 Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122:13731382.
  • 29
    Child LM, Goater JJ, Sanz I, Ritchlin C, Looney R, Zwillich SJ, Schwarz EM 1999 Efficacy of the soluble TNF-a inhibitor (Enbrel) to prevent prosthetic wear debris-induced osteolysis. Arthritis Rheum 42(Suppl.):S154.
  • 30
    Schwarz EM, Lu AP, Goater JJ, Benz EB, Kollias G, Rosier RN, Puzas JE, O'Keefe RJ 2000 TNFa/NFkB signaling in periprosthetic osteolysis. J Orthop Res 18:472480.
  • 31
    Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, MacNaughton WK 1998 Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity. Gastroenterology 115 :101109.
  • 32
    Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC 1998 Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95:1331313318.
  • 33
    Stea S, Visentin M, Granchi D, Melchiorri C, Soldati S, Sudanese A, Toni A, Montanaro L, Pizzoferrato A 1999 Wear debris and cytokine production in the interface membrane of loosened prostheses. J Biomater Sci Polym Ed 10:247257.
  • 34
    Blaine TA, Rosier RN, Puzas JE, Looney RJ, Reynolds PR, Reynolds SD, O'Keefe RJ 1996 Increased levels of tumor necrosis factor-alpha and interleukin-6 protein and messenger RNA in human peripheral blood monocytes due to titanium particles. J Bone Joint Surg Am 78:11811192.
  • 35
    Horowitz SM, Algan SA, Purdon MA 1996 Pharmacologic inhibition of particulate-induced bone resorption. J Biomed Mater Res 31:9196.
  • 36
    Takagi M, Santavirta S, Ida H, Ishii M, Mandelin J, Konttinen YT 1998 Matrix metalloproteinases and tissue inhibitors of metalloproteinases in loose artificial hip joints. Clin Orthop 352:3545.
  • 37
    Goodman SB, Chin RC, Chiou SS, Lee JS 1991 Suppression of prostaglandin E2 synthesis in the membrane surrounding particulate polymethylmethacrylate in the rabbit tibia. Clin Orthop 221:300304.
  • 38
    Goodman SB, Chin RC, Magee FP 1992 Prostaglandin E2 production by the membrane surrounding loose and fixated cemented tibial hemiarthroplasties in the rabbit knee. Clin Orthop 288:283287.
  • 39
    Kjaersgaard-Andersen P, Schmidt SA, Pedersen NW, Kristensen SS, Pedersen P 1989 Early radiolucencies following cemented total hip replacement. Influence of postoperative treatment with indomethacin. Orthopedics 12:401406.
  • 40
    Trnka HJ, Zenz P, Zembsch A, Easley M, Ritschl P, Salzer M 1999 Stable bony integration with and without short-term indomethacin prophylaxis. A 5-year follow-up. Arch Orthop Trauma Surg 119:456460.
  • 41
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I 1999 Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 90:551560.
  • 42
    Masaki M, Matsushita M, Wakitani K 1998 Inhibitory effects of JTE-522, a novel prostaglandin H synthase-2 inhibitor, on adjuvant-induced arthritis and bone changes in rats. Inflamm Res 7:187192.
  • 43
    Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA 1996 Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 97:26722679.
  • 44
    Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis GS 1998 Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41:15911602.
  • 45
    Gavett SH, Madison SL, Chulada PC, Scarborough PE, Qu W, Boyle JE, Tiano HF, Lee CA, Langenbach R, Roggli VL, Zeldin DC 1999 Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest 104:721732.
  • 46
    Okada Y, Lorenzo JA, Freeman1 AM, Tomita M, Morham GS, Raisz LG, Pilbeam C 2000 Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 105:823832.
  • 47
    Tsukii K, Shima N, Mochizuki S, Yamaguchi K, Kinosaki M, Yano K, Shibata O, Udagawa N, Yasuda H, Suda T, Higashio K 1998 Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 246:337341.
  • 48
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:35973602.
  • 49
    Nakagawa N, Yasuda H, Yano K, Mochizuki Si, Kobayashi N, Fujimoto H, Shima N, Morinaga T, Chikazu D, Kawaguchi H, Higashio K 1999 Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. Biochem Biophys Res Commun 265:158163.
  • 50
    Wani MR, Fuller K, Kim NS, Choi Y, Chambers T 1999 Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: Synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 140:19271935.
  • 51
    Votta BJ, Bertolini DR 1994 Cytokine suppressive anti-inflammatory compounds inhibit bone resorption in vitro. Bone 15:533538.